NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Inspire Medical Systems, Inc. ("Inspire Medical" or the "Company") (NYSE:INSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Inspire Medical and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 7, 2023, Inspire Medical issued a press release announcing disappointing earnings results for the third quarter of 2023—its first reported revenue miss since becoming a public company in 2018. In the press release, the Company's Chief Executive Officer ("CEO") advised that in tracking the results of the Company's pilot program ...